{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:09:57Z","timestamp":1792091397019,"version":"4.4.0"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chronic kidney disease presents a health challenge that has a complex underlying pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options available today lower the progression of the disease and improve the quality of life but cannot completely cure it. This poses a challenge to the healthcare provider to choose, from the available options, the best way to manage the disease as per the presentation of the patient. As of now, the recommended first line of treatment to control the blood pressure in chronic kidney disease is the administration of renin\u2013angiotensin\u2013aldosterone system modulators. These are represented mainly by the direct renin inhibitor, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. These modulators are varied in their structure and mechanisms of action, hence showing varying treatment outcomes. The choice of administration of these modulators is determined by the presentation and the co-morbidities of the patient, the availability and affordability of the treatment option, and the expertise of the healthcare provider. A direct head-to-head comparison between these significant renin\u2013angiotensin\u2013aldosterone system modulators is lacking, which can benefit healthcare providers and researchers. In this review, a comparison has been drawn between the direct renin inhibitor (aliskiren), angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. This can be of significance for healthcare providers and researchers to find the particular loci of interest, either in structure or mechanism, and to intervene as per the case presentation to obtain the best possible treatment option.<\/jats:p>","DOI":"10.3389\/fphar.2023.1101068","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T02:02:57Z","timestamp":1676253777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Renin\u2013angiotensin\u2013aldosterone pathway modulators in chronic kidney disease: A comparative review"],"prefix":"10.3389","volume":"14","author":[{"given":"Saeed","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00380-012-0260-7","article-title":"Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease","volume":"28","author":"Abe","year":"2013","journal-title":"Heart Vessels"},{"key":"B2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000350142","article-title":"To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease-a Dutch perspective","volume":"37","author":"Adarkwah","year":"2013","journal-title":"Kidney Blood Press Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J. Hypertens."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e0237467","DOI":"10.1371\/journal.pone.0237467","article-title":"The role of patiromer: Comparing OPAL-HK data with untreated real-world patients in the United Kingdom-A retrospective, propensity-matched analysis","volume":"15","author":"Ali","year":"2020","journal-title":"PLoS One"},{"key":"B4","unstructured":"Aliskiren compound summary2022"},{"key":"B5","first-page":"809","article-title":"Aliskiren\u2013an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension","volume":"3","author":"Allikmets","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"B6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2174\/1389450115666140211113040","article-title":"Efficacy and safety profile of aliskiren: Practical implications for clinicians","volume":"9","author":"Angeli","year":"2014","journal-title":"Curr. Drug Saf."},{"key":"B7","unstructured":"Inhibitors market analysis\n            Angiotensin Converting Enzymes (Ace)\n          2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Int"},{"key":"B9","volume-title":"Improving prognosis of nondiabetic chronic renal insufficiency: The role of ACE inhibitors","author":"Bakris","year":"2000"},{"key":"B10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1524-6175.2002.01641.x","article-title":"ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence?","volume":"4","author":"Bakris","year":"2002","journal-title":"J. Clin. Hypertens."},{"key":"B149","doi-asserted-by":"publisher","first-page":"151\u2013161","DOI":"10.1001\/jama.2015.7446","article-title":"AMETHYST-DN investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/chf.12011","article-title":"When conventional heart failure therapy is not enough: Angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?","volume":"19","author":"Bangalore","year":"2013","journal-title":"Congest. Heart Fail"},{"key":"B12","first-page":"1714","article-title":"[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure","volume":"31","author":"Bernadet-Monrozies","year":"2002","journal-title":"La Presse m\u00e9dicale"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin\u2013angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1039\/c1ob05148b","article-title":"Effect of peptide-based captopril analogues on angiotensin converting enzyme activity and peroxynitrite-mediated tyrosine nitration","volume":"9","author":"Bhuyan","year":"2011","journal-title":"Org. Biomol. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/vhrm.s12187449","article-title":"Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: Results from the AMADEO study","volume":"5","author":"Bichu","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"B16","first-page":"461","article-title":"Using ACE inhibitors appropriately","volume":"66","author":"Bicket","year":"2002","journal-title":"Am. Fam. Physician"},{"key":"B17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/187569211798377135","article-title":"Top three pharmacogenomics and personalized medicine applications at the nexus of renal pathophysiology and cardiovascular medicine","volume":"9","author":"Bochud","year":"2011","journal-title":"Curr. Pharmacogenomics Person. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"73S-78S","DOI":"10.1592\/phco.19.7.73s.30946","article-title":"Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations","volume":"19","author":"Bottorff","year":"1999","journal-title":"special populations Phamacotherapy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.cir.103.6.904","article-title":"Angiotensin II type 1 receptor blockers","volume":"103","author":"Burnier","year":"2001","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.xkme.2020.04.002","article-title":"Renin-angiotensin system blockade in advanced kidney disease: Stop or continue?","volume":"2","author":"Burnier","year":"2020","journal-title":"Kidney Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/molecules25020295","article-title":"Considerations for docking of selective angiotensin-converting enzyme inhibitors","volume":"25","author":"Caballero","year":"2020","journal-title":"Molecules"},{"key":"B23","unstructured":"Common drug review2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1093\/ndt\/gfy001","article-title":"Comparative efficacy of individual renin\u2013angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: A network meta-analysis","volume":"33","author":"Cai","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1001971","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin\u2013angiotensin system blockade in adult patients with diabetes mellitus: A systematic review with network meta-analyses","volume":"13","author":"Catala-Lopez","year":"2016","journal-title":"PLoS Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/jch.12795","article-title":"Acute kidney injury in elderly patients with chronic kidney disease: Do angiotensin\u2010converting enzyme inhibitors carry a risk?","volume":"18","author":"Chaumont","year":"2016","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/hr.2012.185","article-title":"Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: A meta-analysis","volume":"36","author":"Chen","year":"2013","journal-title":"Hypertens. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.kint.2018.12.025","article-title":"Blood pressure in chronic kidney disease: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.23876\/j.krcp.21.900","article-title":"Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease","volume":"40","author":"Cho","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/13696998.2017.1311266","article-title":"Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease","volume":"20","author":"Clark","year":"2017","journal-title":"J. Med. Econ."},{"key":"B32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC. Heart Fail."},{"key":"B33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2337\/ds20-0071","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and the kidney","volume":"34","author":"DeFronzo","year":"2021","journal-title":"Diabetes Spectr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2008111144","article-title":"Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria","volume":"20","author":"Delea","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0886022X.2014.900425","article-title":"Update on role of direct renin inhibitor in diabetic kidney disease","volume":"36","author":"Dhakarwal","year":"2014","journal-title":"Ren. Fail"},{"key":"B36","first-page":"102","article-title":"Neprilysin inhibition and chronic kidney disease","volume":"34","author":"Di Lullo","year":"2017","journal-title":"G. Ital. Nefrol. ital. nefrol organo uff."},{"key":"B37","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ki.1984.114","article-title":"Elimination kinetics of captopril in patients with renal failure","volume":"25","author":"Duchin","year":"1984","journal-title":"Kidney Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1L-20L","DOI":"10.1016\/s0002-9149(01)01878-1","article-title":"The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data","volume":"88","author":"Dzau","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"B39","volume-title":"Commentary on NICE guideline (NG136)\u2018Hypertension in adults: Diagnosis and management including proposals for blood pressure management in patients with chronic kidney disease","author":"Fish","year":"2021"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"B41","article-title":"Physiology, renin angiotensin system","volume-title":"StatPearls [Internet]","author":"Fountain","year":"2022"},{"key":"B42","unstructured":"Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in A real life population of complicated type 2 diabetes\u2013contraindications and opportunities\n            GantC. M.\n            OosterwijkM. M.\n            BinnenmarsS. H.\n            NavisG. J.\n            HaverkateH.\n            BakkerS. J. L.\n          2022"},{"key":"B43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2215\/CJN.02920320","article-title":"Benefits of continuing RAAS inhibitors in advanced CKD","volume":"15","author":"Gaudreault-Tremblay","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.97354","volume-title":"Role of the renin-angiotensin-aldosterone system in various disease processes: An overview","author":"Gelen","year":"2021"},{"key":"B45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2165\/00019053-199610060-00006","article-title":"Formulary management of ACE inhibitors","volume":"10","author":"Gerbrandt","year":"1996","journal-title":"Pharmacoeconomics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1365-2125.1984.tb02538.x","article-title":"Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients","volume":"18","author":"Giudicelli","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ihj.2012.06.015","article-title":"ALTITUDE halted: Adverse events when aliskiren added to ACEI, ARB therapy","volume":"64","author":"Guha","year":"2012","journal-title":"Indian Heart J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1055\/a-1138-0959","article-title":"Effects of ACE inhibitors and angiotensin receptor blockers in normotensive patients with diabetic kidney disease","volume":"52","author":"He","year":"2020","journal-title":"Horm. Metab. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Int"},{"key":"B51","volume-title":"Angiotensin converting enzyme inhibitors (ACEI)","author":"Herman","year":"2017"},{"key":"B52","unstructured":"Angiotensin II receptor blockers (ARB)\n            HillR. D.\n            VaidyaP. N.\n          2020"},{"key":"B53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1524-4733.2009.00668.x","article-title":"Cost\u2010effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: A modeled analysis","volume":"13","author":"Howard","year":"2010","journal-title":"Value Health"},{"key":"B54","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2165\/00003088-199324030-00005","article-title":"Clinical pharmacokinetics of angiotensin-converting enzyme (ACE) inhibitors in renal failure","volume":"24","author":"Hoyer","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"B56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/hr.2009.175","article-title":"Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction","volume":"33","author":"Ito","year":"2010","journal-title":"Hypertens. Res."},{"key":"B57","article-title":"Aliskiren","volume-title":"StatPearls","author":"Jacobs","year":"2021"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication\u2014Worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Kidney Int."},{"key":"B59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MNH.0000000000000659","article-title":"TaleNeprilysin and Neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B60","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ndt\/gfu269","article-title":"Neprilysin inhibition in chronic kidney disease","volume":"30","author":"JudgeP","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"B61","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40262-012-0003-z","article-title":"Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis","volume":"51","author":"Khadzhynov","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","article-title":"Ramipril versus placebo in kidney transplant patients with proteinuria: A multicentre, double-blind, randomised controlled trial","volume":"4","author":"Knoll","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2223\u20132233","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"B64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin\u2013angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann. Intern Med."},{"key":"B65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"May. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin. Nephrol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: Fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/jpm11040252","article-title":"Effects of CYP3A5 polymorphism on rapid progression of chronic kidney disease: A prospective, multicentre study","volume":"11","author":"Lee","year":"2021","journal-title":"J. Pers. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6904-6-1","article-title":"Human physiologically based pharmacokinetic model for ACE inhibitors: Ramipril and ramiprilat","volume":"6","author":"Levitt","year":"2006","journal-title":"BMC Clin. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12872-020-01579-x","article-title":"The relationship of plasma renin, angiotensin, and aldosterone levels to blood pressure variability and target organ damage in children with essential hypertension","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1503\/cmaj.121468","article-title":"Effects of intensive blood pressure lowering on the progression of chronic kidney disease: A systematic review and meta-analysis","volume":"185","author":"Lv","year":"2013","journal-title":"CMAJ"},{"key":"B72","first-page":"1","volume-title":"Captopril","author":"Marte","year":"2022"},{"key":"B73","doi-asserted-by":"publisher","first-page":"33S16","DOI":"10.1097\/00005344-199900001-00004","article-title":"Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. The ACE inhibition in progressive renal insufficiency (AIPRI) study group","author":"Maschio","year":"1999","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/hy09t1.094234","article-title":"Angiotensin II and renal fibrosis","volume":"38","author":"Mezzano","year":"2001","journal-title":"Hypertension"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Review: Angiotensin II type 1 receptor blockers: Class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B76","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co\u2010transport\u20102 inhibitors in type 2 diabetes: A meta\u2010analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"B77","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1161\/HYPERTENSIONAHA.106.085563","article-title":"Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition","volume":"50","author":"Moore","year":"2007","journal-title":"Hypertension"},{"key":"B78","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease","volume":"75","author":"Munar","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"B79","volume-title":"Potassium binders for chronic hyperkalaemia in people with chronic kidney disease CDSR","author":"Natale","year":"2020"},{"key":"B80","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2165\/00002018-199615030-00005","article-title":"ACE inhibitors and the kidney. A risk-benefit assessment","volume":"15","author":"Navis","year":"1996","journal-title":"Drug Saf."},{"key":"B81","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur. Heart J."},{"key":"B82","unstructured":"Treatment Chronic kidney diseases2022"},{"key":"B83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/ph2030118","article-title":"Aliskiren: Just a new drug for few selected patients or an innovative molecule predestinated to replace arbs and ace-inhibitors?","volume":"2","author":"Novo","year":"2009","journal-title":"Pharm. (Basel)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00003495-199000392-00006","article-title":"Angiotensin-converting enzyme inhibitors in chronic renal failure","volume":"39","author":"Opsahl","year":"1990","journal-title":"Drugs"},{"key":"B151","doi-asserted-by":"publisher","first-page":"222\u2013231","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/PGPM.S52763","article-title":"Developments in renal pharmacogenomics and applications in chronic kidney disease","volume":"7","author":"Padull\u00e9s","year":"2014","journal-title":"Pharmgenomics Pers. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/TP.0b013e3182827a43","article-title":"Effects of ACE inhibitors on long-term outcome of renal transplant recipients: A randomized controlled trial","volume":"95","author":"Paoletti","year":"2013","journal-title":"Transplantation"},{"key":"B87","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B88","first-page":"18173","article-title":"Aliskiren improves renal morphophysiology and inflammation in Wistar rats with 2K1C renovascular hypertension","volume":"18","author":"Pereira","year":"2019","journal-title":"Histol. Histopathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/ajhp\/57.suppl_1.S3","article-title":"Overview of the angiotensin-converting-enzyme inhibitors","volume":"57","author":"Piepho","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B90","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: Current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"HTN"},{"key":"B92","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"B94","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/FJC.0b013e3182676f06","article-title":"An integrated physiology-based model for the interaction of RAA system biomarkers with drugs","volume":"60","author":"Ramusovic","year":"2012","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1185\/03007990802336541","article-title":"Direct renin inhibition: An evaluation of the safety and tolerability of aliskiren","volume":"24","author":"Rashid","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-88154-2","article-title":"Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases","volume":"11","author":"Rasool","year":"2021","journal-title":"Sci. Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"68","author":"Remuzzi","year":"2005","journal-title":"Kidney Int. Suppl."},{"key":"B98","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1586\/ecp.10.143","article-title":"Modeling and predicting drug pharmacokinetics in patients with renal impairment","volume":"4","author":"Rowland Yeo","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2217\/14622416.10.3.463","article-title":"Significance of genetic polymorphisms of the renin\u2013angiotensin\u2013aldosterone system in cardiovascular and renal disease","volume":"10","author":"Rudnicki","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B100","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbamem.2014.12.004","article-title":"Comparative study of interactions of aliskiren and AT1 receptor antagonists with lipid bilayers","volume":"1848","author":"Sadeghpour","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B101","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/liv.14272","article-title":"Pathways of hepatic and renal damage through non\u2010classical activation of the renin\u2010angiotensin system in chronic liver disease","volume":"40","author":"Sanso\u00e8","year":"2020","journal-title":"Liver Int."},{"key":"B102","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1254\/jphs.12r03cr","article-title":"Renin\u2013angiotensin system, hypertension, and chronic kidney disease: Pharmacogenetic implications","volume":"120","author":"Santos","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2174\/0929867325666180307110908","article-title":"Chronic kidney disease and the search for new biomarkers for early diagnosis","volume":"25","author":"Saucedo","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2165\/00019053-200119050-00005","article-title":"Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: Economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance","volume":"19","author":"Sch\u00e4dlich","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"B106","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/1060028016640794","article-title":"Potassium-binding agents to facilitate renin-angiotensin-aldosterone system inhibitor therapy","volume":"50","author":"Schaefer","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"B107","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B108","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.ackd.2010.11.001","article-title":"Hypertension in moderate-to-severe nondiabetic CKD patients","volume":"18","author":"Segura","year":"2011","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B109","first-page":"1111","article-title":"Renin inhibitors in diabetes and hypertension: An update","volume":"13","author":"Sen","year":"2014","journal-title":"EXCLI J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2165\/00003088-199120050-00006","article-title":"Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency","volume":"20","author":"Sica","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"B111","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/00003088-200038060-00005","article-title":"Pharmacokinetics and blood pressure response of losartan in end-stage renal disease","volume":"38","author":"Sica","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"B112","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00004872-199507001-00007","article-title":"The pharmacokinetics of losartan in renal insufficiency","volume":"13","author":"Sica","year":"1995","journal-title":"J. Hypertens. Suppl."},{"key":"B113","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/1574887113666180726103648","article-title":"Successful use of aliskiren in a case of IgA-mesangial glomerulonephritis unresponsive to conventional therapies","volume":"14","author":"Simeoni","year":"2019","journal-title":"Rev. Recent Clin. Trials"},{"key":"B114","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: Are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/0973-7847.79097","article-title":"Aliskiren: A new renin inhibitor as anti-hypertensive","volume":"5","author":"Tabassum","year":"2011","journal-title":"Appl. Pharm. Sci. (Issue)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/ndt\/gfaa085","article-title":"Direct renin inhibition in non-diabetic chronic kidney disease (DRINK): A prospective randomized trial","volume":"36","author":"Tang","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"B118","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00228-010-0836-z","article-title":"Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren","volume":"66","author":"Tapaninen","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B119","unstructured":"Basics, side effects, reviews and more\n            TekturnaAliskiren (\n          2022"},{"key":"B120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11897-020-00463-1","article-title":"Impact of sacubitril-valsartan on mark ers of glomerular function","volume":"17","author":"Tersalvi","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"B121","first-page":"141","volume":"3","author":"Tinawi","year":"2020","journal-title":"Potassium Bind. Arch. Intern. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.bmcl.2006.07.034","article-title":"The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme","volume":"16","author":"Tzakos","year":"2006","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B123","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2125.1982.tb01991.x","article-title":"Enalapril maleate and a lysine analogue (MK\u2010521): Disposition in man","volume":"14","author":"Ulm","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B124","article-title":"Chronic renal failure","volume-title":"StatPearls [Internet]","author":"Vaidya","year":"2022"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/0091270008323258","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P\u2010glycoprotein in the disposition of aliskiren","volume":"48","author":"Vaidyanathan","year":"","journal-title":"J. Clin. Pharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00003088-200847080-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of aliskiren","volume":"47","author":"Vaidyanathan","year":"","journal-title":"Clin. Pharmacokinet."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-021-01555-5","article-title":"Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies","volume":"81","author":"Valdivielso","year":"2021","journal-title":"Drugs"},{"key":"B128","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.2215\/CJN.08900722","article-title":"Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes","volume":"17","author":"Vart","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1753944710369682","article-title":"Aliskiren versus ramipril in hypertension","volume":"4","author":"Verdecchia","year":"2010","journal-title":"Ther. Adv. Cardiovasc Dis."},{"key":"B131","unstructured":"Aliskiren market size and forecast2022"},{"key":"B132","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.compchemeng.2017.03.027","article-title":"A pharmacokinetic\/pharmacodynamic model of ACE inhibition of the renin-angiotensin system for normal and impaired renal function","volume":"104","author":"Versypt","year":"2017","journal-title":"Comput. Chem. Eng."},{"key":"B133","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: Data from a prospective registry","volume":"73","author":"Vicent","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1124\/dmd.106.013797","article-title":"Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers","volume":"35","author":"Waldmeier","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"B135","unstructured":"High blood pressure and angiotensin II receptor blockers (ARBs)2022"},{"key":"B136","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/s0006-291x(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B138","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1470320312467560","article-title":"Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial","volume":"15","author":"Wu","year":"2014","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B139","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Hypertens. Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2022.08.016","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.bbamem.2013.12.012","article-title":"Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach","volume":"1838","author":"Zervou","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B143","doi-asserted-by":"publisher","first-page":"29127","DOI":"10.1074\/jbc.M115.689000","article-title":"Structural basis for ligand recognition and functional selectivity at angiotensin receptor","volume":"290","author":"Zhang","year":"","journal-title":"J. Biol. Chem."},{"key":"B144","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cell.2015.04.011","article-title":"Structure of the angiotensin receptor revealed by serial femtosecond crystallography","volume":"161","author":"Zhang","year":"","journal-title":"Cell."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2147\/DDDT.S75111","article-title":"Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: A meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-020-01442-z","article-title":"Clinical efficacy, safety and tolerability of aliskiren monotherapy (AM): An umbrella review of systematic reviews","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B147","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/eurheartj\/ehx502.p2093","article-title":"P2093Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in diabetics with cardiovascular disease or risk: A systematic review and meta-analysis of 13, 395 patients","volume":"38","author":"Zheng","year":"2017","journal-title":"Eur. Heart J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1101068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T02:03:20Z","timestamp":1676253800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1101068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":151,"alternative-id":["10.3389\/fphar.2023.1101068"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1101068","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"1101068"}}